The consortium aims at revolutionising healthcare by mapping, understanding, and targeting human cells during disease.
LifeTime will develop and integrate several emerging disruptive technologies (single-cell multi-omics, advanced imaging, machine learning/AI, personalised disease models). LifeTime is committed to promote better research value in and for Europe to advance understanding and early diagnosis, interception, treatment of a wide range of diseases towards innovation and personalized medicine.
Following two competitive rounds of peer review, LifeTime has received 1M€ from the European Commission to translate its vision into a roadmap for Europe.
The LifeTime Vision
LifeTime’s unifying goal is to understand and treat human cells during disease. The consequent deeper understanding of the molecular principles that drive the progression between healthy and disease cell states will promote breakthroughs in modern medicine and the advancement of precision medicine.
In the long-term LifeTime technologies will inform the physician about the molecular history of a patient's tissues, their future, and the consequences of perturbations or medical treatments, leading to early diagnosis and effective interception of disease.
Three Technology pillars
LifeTime aims to revolutionise healthcare by developing and integrating several emerging, disruptive technologies:
- single-cell biology
- artificial intelligence
LifeTime technologies will track and decipher the activity of our genomes in individual cells as they progress through time (ageing or disease) – "LifeTime".
The initiative is supported by more than 80 companies and by major European research organisations such as:
- Helmholtz Association in Germany
- National Centre for Scientific Research (CNRS) and INSERM in France
- Wellcome Trust in the United Kingdom
- Netherlands Organisation for Scientific Research (NWO)
- EU-LIFE Alliance
- national science academies
Header image by Spencer Phillips / EMBL-EBI